Double-Blind,Randomized,Placebo-Controlled Efficacy & Safety Study of EUFLEXXA™ for Treatment of OA of the First CMC

NCT00423371 | Completed Phase 2

• 1 other identifier: 2006-02
• Study Type: interventional
• Target: 79
• Locations: 1 country
• Sites: 1

Brief Summary

This multicenter, double-blind, randomized, parallel-group, active-controlled trial will be performed in approximately 80 subjects with chronic idiopathic osteoarthritis (OA) of the first carpo-metacarpal joint (CMC).

Conditions

Osteoarthritis

Keywords

first Carpometacarpal (CMC) Joint

Outcome Measures

Primary Outcomes (1)

• Mean change in pain scores as reported by the patient on the AUSCAN Index pain subscale

  weeks 0 and 26

Secondary Outcomes (3)

• Mean change in stiffness and function scores as reported by the patient on the AUSCAN Index stillness and function subscale

  weeks 0 and 26

• Change in Patient Global Assessment of Symptoms measured by 100mm visual analog scale (VAS)

  Weeks 0 and 26

• Number of tablets of rescue medication used between visits

  Weeks 0 and 26

Study Arms (2)

EUFLEXXA™

EXPERIMENTAL

Device: sodium hyaluronate

Placebo

PLACEBO COMPARATOR

Device: placebo

Interventions

sodium hyaluronate DEVICE

EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.

Also known as: EUFLEXXA™

EUFLEXXA™

placebo DEVICE

Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.

Placebo

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Men or women ≥40 years of age
• Pain due to primary OA of the first CMC joint present for at least half the days of the previous month AND a mean combined pain score ≥ 30 mm out of 100 mm of the 5 pain questions on the AUSCAN Index Pain Subscale (See Appendix 1)
• A series of X-rays confirming OA of the first CMC joint of the target thumb obtained at screening with a stage of 2, 3, or 4 according to Grading Scale in Appendix 3.
• Ability and willingness to use only acetaminophen as the analgesic (rescue) study medication
• The acetaminophen dose must not exceed 4 grams/day (4000 mg)
• If subject has known chronic liver disease, the maximum dose of acetaminophen must not exceed 2 grams/day (2000 mg)
• The subject must be willing and able to discontinue acetaminophen at least 24 hours prior to all study-specific visits
• The study specific acetaminophen provided will only be used for thumb/joint pain.
• Willingness and ability to complete efficacy and safety questionnaires and ability to read and understand study instructions
• Signed study-specific Subject Informed Consent Form

You may not qualify if:

• Any major injury to the target thumb within the 6 months prior to the Screening Visit
• Anyone having Carpal Tunnel Syndrome (CTS), DeQuervain's tenosynovitis, trigger finger, or a ganglion cyst of the target hand ONLY IF there is evidence of extreme atrophy AND two-point average discrimination is greater than 10-mm, OR if the pain from these conditions renders the subject unable to objectively assess OA pain in the target hand
• Any surgery to the target joint within the 12 months prior to the Screening Visit
• Regular use of assistive devices such as a cane or crutch or a CTS brace
• Concomitant rheumatic disease (rheumatoid arthritis, lupus arthropathy, psoriatic arthritis)
• History of chondrocalcinosis in the target joint
• Gout exacerbation in any joint in the past 6 months
• X-ray findings of acute fractures, severe loss of bone density, and/or severe bone or joint deformity in the target joint
• Significant target joint infection or skin disorder/infection within the 3 months prior to study enrollment
• Known hypersensitivity to acetaminophen, EUFLEXXA™, or Phosphate Buffered Saline solution
• Women of childbearing potential who are pregnant, nursing, or planning to become pregnant, and those who do not agree to remain on an acceptable method of birth control throughout the entire study period
• Recurrent medical history of severe allergic or immune-mediated reactions or other immune disorders
• Current treatment or treatment within the previous 2 years prior to the Screening Visit for any malignancy unless specific written permission is provided by the Sponsor (excluding basal cell or squamous cell carcinoma of the skin)
• Active liver disease based on liver profile of AST, ALT, and conjugated bilirubin \>2 times the upper limit of normal
• Renal insufficiency based on serum creatinine \>2.0 mg/dL

Sponsors & Collaborators

• Ferring Pharmaceuticals: lead

Study Sites (1)

All Florida Orthopedic Association

St. Petersburg, Florida, 33703, United States

Location

MeSH Terms

Conditions

Osteoarthritis; Capillary Malformations, Congenital, 1

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases

Study Officials

• Clinical Development Support

  Ferring Pharmaceuticals

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: January 17, 2007
• First Posted: January 18, 2007
• Study Start: December 1, 2006
• Primary Completion: September 1, 2007
• Study Completion: September 1, 2007
• Last Updated: May 19, 2011

Record last verified: 2011-05

Locations

US (1)